Loading
A phase 2/3 trial testing INBRX-106 in head and neck squamous cell carcinoma, active and no longer recruiting.
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC is a phase 2/3 interventional study registered as NCT06295731, led by Inhibrx Biosciences, and active but no longer recruiting on the registry. Official title: A Phase 2/3, Randomised Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN). Planned enrolment is 410 participants (estimated). The study started in 2024-05-14 and primary completion is expected in 2029-05. No results have been posted on ClinicalTrials.gov.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.